This analysis reveals enhanced kidney-targeting delivery of oligonucleotide therapy via peptide conjugation, suggesting improved efficacy and safety.
Targeted drug delivery has emerged as a crucial strategy to enhance efficacy and minimize side effects from off-target interactions, a particularly relevant approach for kidney diseases, where many treatments suffer from poor targeting efficiency. In this study, we benchmarked a series of peptides previously identified for their kidney-targeting potential, utilizing them as targeting moieties for an oligonucleotide aimed at repressing HIF-1α expression in renal tubular cells. The peptides were synthesized, radiolabeled, and evaluated for their biodistribution profiles in mice. The best-performing peptide was conjugated to the oligonucleotide of interest, leveraging its kidney-targeting properties to optimize the delivery. We demonstrated that conjugation of the oligonucleotide to a kidney-targeting peptide preserved its repressing HIF-1α activity, while increasing accumulation 10-fold in the kidneys. The results from this study offer valuable insights into the potential of kidney-targeting peptides as a novel strategy to improve the efficacy and safety of therapies for kidney diseases.
No takes yet. Share an insight, caveat, or question.
Mannes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: